Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could an apple extract fight inflammation and slow aging?

NCT ID NCT07678346

Disease control Sponsor: Nutraland USA, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests whether a daily apple extract called AppleX™, rich in the compound fisetin, can lower inflammation and improve vitality in adults aged 45 to 70 who have signs of low-grade inflammation. Participants take either the extract or a placebo for 24 weeks. Researchers measure changes in blood inflammation markers, energy levels, joint comfort, and biological aging.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AppleX™ apple extract (standardized to 15% fisetin)
What this could lead to
If it works, this could point toward a natural supplement to reduce inflammation and support healthier aging.
What could go wrong
This is a small pilot study, so results may not apply widely. The extract may not lower inflammation or affect aging as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 45-70 years at time of enrollment * Meets questionnaire-based inflammatory enrichment criteria (at least 2 of 5 risk factors, per Section 4.2) * Non-smoker (no tobacco or nicotine use within 6 months of enrollment) * Willing and able to maintain stable diet, exercise habits, and supplement use throughout the 24-week study period * No major medication changes planned during the study period * Willing to perform home-based DBS collections at T0, T12, and T24 * Access to a smartphone or computer to complete eConsent and online questionnaires * Able to provide informed consent via the Alethios eConsent platform Exclusion Criteria: * Current use of prescription anti-inflammatory medications including NSAIDs (regular use ≥3x/week), corticosteroids, or DMARDs * Diagnosis of an autoimmune or inflammatory disease (e.g., rheumatoid arthritis, lupus, IBD, multiple sclerosis) * Active or unstable cardiovascular disease requiring medication changes during the study period * History of cancer within the past 5 years (except non-melanoma skin cancer) * Regular use of supplemental fisetin, quercetin, or resveratrol within 30 days of enrollment * Pregnancy, breastfeeding, or planning to become pregnant during the study * Known allergy to apple or apple-derived products * Body mass index (BMI) \>40 kg/m²

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy adult participants are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy adult participants Healthy aging Systemic inflammation (HSCRP) Vitality

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Alethios, Inc.

    San Francisco, California, 94109, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.